WallStreetZenWallStreetZen

NASDAQ: ABCL
Abcellera Biologics Inc Stock

$4.49+0.20 (+4.66%)
Updated Mar 27, 2024
ABCL Price
$4.49
Fair Value Price
-$3.93
Market Cap
$1.31B
52 Week Low
$3.87
52 Week High
$8.05
P/E
-8.8x
P/B
1.14x
P/S
43.42x
PEG
N/A
Dividend Yield
N/A
Revenue
$38.03M
Earnings
-$146.40M
Gross Margin
100%
Operating Margin
-457.67%
Profit Margin
-385%
Debt to Equity
0.29
Operating Cash Flow
-$44M
Beta
1.24
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A

ABCL Overview

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ABCL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ABCL ($4.49) is overvalued by 214.25% relative to our estimate of its Fair Value price of -$3.93 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ABCL ($4.49) is not significantly undervalued (214.25%) relative to our estimate of its Fair Value price of -$3.93 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ABCL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ABCL due diligence checks available for Premium users.

Be the first to know about important ABCL news, forecast changes, insider trades & much more!

ABCL News

Valuation

ABCL fair value

Fair Value of ABCL stock based on Discounted Cash Flow (DCF)
Price
$4.49
Fair Value
-$3.93
Undervalued by
214.25%
ABCL ($4.49) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ABCL ($4.49) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ABCL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ABCL price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-8.8x
Industry
14.3x
Market
44.45x

ABCL price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.14x
Industry
6.2x
ABCL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ABCL's financial health

Profit margin

Revenue
$9.2M
Net Income
-$47.2M
Profit Margin
-513.7%
ABCL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ABCL's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$1.5B
Liabilities
$335.8M
Debt to equity
0.29
ABCL's short-term assets ($871.99M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ABCL's short-term assets ($871.99M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ABCL's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ABCL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$19.6M
Investing
-$24.3M
Financing
$3.8M
ABCL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ABCL vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ABCL$1.31B+4.66%-8.80x1.14x
VRNA$1.33B+2.23%-22.92x5.35x
SYRE$1.34B-1.62%-0.75x7.27x
PRTA$1.35B+1.66%-9.12x2.41x
VIR$1.36B+1.30%-2.20x0.86x

Abcellera Biologics Stock FAQ

What is Abcellera Biologics's quote symbol?

(NASDAQ: ABCL) Abcellera Biologics trades on the NASDAQ under the ticker symbol ABCL. Abcellera Biologics stock quotes can also be displayed as NASDAQ: ABCL.

If you're new to stock investing, here's how to buy Abcellera Biologics stock.

What is the 52 week high and low for Abcellera Biologics (NASDAQ: ABCL)?

(NASDAQ: ABCL) Abcellera Biologics's 52-week high was $8.05, and its 52-week low was $3.87. It is currently -44.22% from its 52-week high and 16.02% from its 52-week low.

How much is Abcellera Biologics stock worth today?

(NASDAQ: ABCL) Abcellera Biologics currently has 292,782,152 outstanding shares. With Abcellera Biologics stock trading at $4.49 per share, the total value of Abcellera Biologics stock (market capitalization) is $1.31B.

Abcellera Biologics stock was originally listed at a price of $50.01 in Dec 14, 2020. If you had invested in Abcellera Biologics stock at $50.01, your return over the last 3 years would have been -91.02%, for an annualized return of -55.22% (not including any dividends or dividend reinvestments).

How much is Abcellera Biologics's stock price per share?

(NASDAQ: ABCL) Abcellera Biologics stock price per share is $4.49 today (as of Mar 27, 2024).

What is Abcellera Biologics's Market Cap?

(NASDAQ: ABCL) Abcellera Biologics's market cap is $1.31B, as of Mar 28, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Abcellera Biologics's market cap is calculated by multiplying ABCL's current stock price of $4.49 by ABCL's total outstanding shares of 292,782,152.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.